"Epirubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
| Descriptor ID |
D015251
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175.200 D04.615.562.050.200.175.200 D09.408.051.059.200.175.200
|
| Concept/Terms |
Epirubicin- Epirubicin
- 4'-Epidoxorubicin
- 4' Epidoxorubicin
- 4'-Epi-Doxorubicin
- 4' Epi Doxorubicin
- 4'-Epi-Adriamycin
- 4' Epi Adriamycin
- 4'-Epiadriamycin
- 4' Epiadriamycin
- 4'-Epi-DXR
- 4' Epi DXR
Ellence- Ellence
- Pharmorubicin
- Farmorubicine
- Farmorubicin
|
Below are MeSH descriptors whose meaning is more general than "Epirubicin".
Below are MeSH descriptors whose meaning is more specific than "Epirubicin".
This graph shows the total number of publications written about "Epirubicin" by people in this website by year, and whether "Epirubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epirubicin" by people in Profiles.
-
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220.
-
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 11; 18(11):1467-1482.
-
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. J Clin Oncol. 2017 02; 35(4):475-477.
-
Molecular profiling in gastric cancer: examining potential targets for chemotherapy. J Surg Oncol. 2014 Sep; 110(3):302-6.
-
Schedule-dependent effects of kappa-selenocarrageenan in combination with epirubicin on hepatocellular carcinoma. Asian Pac J Cancer Prev. 2014; 15(8):3651-7.
-
Prognosis of patients with hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization: risk factors for one-year recurrence and two-year mortality (preliminary data). Intern Med. 2013; 52(8):847-53.
-
Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet Genomics. 2011 Sep; 21(9):552-8.
-
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1147-53.
-
Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009; 27(11):947-61.
-
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97.